The presence of variable degrees of cognitive impairment, extending from severe mental retardation to specific deficits, in patients with dystrophinopathies is a well-recognized problem.
Introduction
The presence of nonprogressive cognitive impairment is now widely accepted and well recognized as a common feature in a substantial proportion of patients with Duchenne muscular dystrophy (DMD), a disorder that is caused by mutations in the dystrophin gene. Duchenne himself had already noted a 'character obtus' of many of the DMD children. More specific studies, such as the meta-analysis carried out by Emery documenting IQ in a total of 721 DMD patients had also provided valuable information (1). This meta-analysis showed that the overall mean IQ was 82 (approximately one standard deviation below the population mean), 19% had an IQ lower than 70 (the generally accepted cut-off point for a diagnosis of MR) and 3% had an IQ of less than 50 (severe MR). In this meta-analysis a specific deficit in verbal rather than performance IQ, with a mean difference of seven or eight point was also highlighted. Weakness of the IQ with a tendency that verbal IQ is more affected than performance IQ was subsequently reported by Billard and others (2) (3) (4) . In patients with
Becker muscular dystrophy, which is milder than DMD in terms of muscular disability but is caused by defects in the same gene, cognitive deficit seems to be less frequent and approximately 10% have an IQ lower than 70 (5, 6) .
Several lines of evidence suggest that the weakness in IQ is likely to be related to mutations in the dystrophin gene (1, 7, 8) . With the identification of the dystrophin gene, which is mutated in DMD and BMD, our understanding of the molecular pathology of the muscular deficit spectrum has been greatly improved, but the aetiology of the intellectual deficit associated with DMD/BMD remains elusive. As 60 to 70% of patients with DMD and BMD have an intragenic deletion (9, 10) , there have been several genotype-phenotype studies, but no consistent correlation between type, site or extent of deletion and IQ has emerged (3, 11, 12) . One might argue that these early studies did not take into account the complex genomic organization of the dystrophin gene and the diversity of isoforms produced either by alternative, or internal promoters (7) . In addition to the full-length dystrophin isoforms (427 kDa) that derive from three independent alternative promoters, named as muscle, brain and Purkinje promoters that regulate spatio-temporal dystrophin expression in muscle tissues, CNS structures and cell types (13) (14) (15) , the dystrophin gene has at least four internal promoters that give rise to shorter dystrophin products (Dp260, Dp140, Dp116 and Dp71) lacking the actin binding terminus but retaining the cystein rich and carboxy-terminus domains. The most abundant dystrophin product in the brain is Dp71 (71 kDa product) that has its promoter region and specific first exon between exons 62 and 63 (7 kb upstream to exon 63) (16) (17) (18) . Even though these findings are taken into consideration, it is still difficult to predict the consequences of defects either in the full length dystrophin and/or in shorter isoforms on the development of cognitive functions, though a number of findings have suggested that rearrangements located in the second part of the gene seem to be preferentially associated with cognitive impairment than mutations in the proximal part (7, 11, 12, 19, 20) . In particular, a large study of 66 DMD patients comparing deletions involving the Dp140 isoform with deletions presumably not altering Dp140 expression revealed a significant association between distal macrodeletions and cognitive impairment (21) . Potential implication of Dp140 in cognitive impairment was also highlighted in a study reported by Bardoni et al. (22) who showed a statistically significant correlation between the absence of Dp140 promoter and the presence of MR in BMD patients. However, in all these phenotype-genotype studies, no systematic correlation was found and only trends for association were pointed out. More recently, consistent correlation with MR has emerged for mutations located in Dp71 coding region. Indeed, several reports (8, 19, (23) (24) (25) described limited number of mutations that extend 3' of exon 63 and almost all of them highlighted the presence of severe mental retardation. However, to our knowledge, no large studies comparing consequences on cognitive functions of mutations differing exclusively by their consequences of Dp71 expression have been reported. Here we present clinical, cognitive, molecular and expression data on a cohort of 81 DMD/BMD with mutations predicted to affect either all dystrophin products including Dp71, or all dystrophin products except Dp71. Interestingly, phenotype/genotype correlations provide convincing data indicating that severe MR results from loss of function of all dystrophin products, and Dp71 deficit appears as a worsening factor of cognitive impairment, that contributes in the severity of MR and accounts for the equivalent of 2 SD downward shift of the intelligence quotient.
Results
In order to assess the potential contribution of Dp71, in the pathogeny of the severity of the cognitive impairment frequently observed in dystrophinopathies, we undertook a retrospective comparative study in two large groups of patients differing by mutations consequences on Dp71 expression and function. The two groups of patients were defined on the basis of molecular abnormalities in the DMD gene. In the first group of patient (Group I) mutations in the DMD gene are predicted to affect all dystrophin products, including Dp71, and in the second group (Group II), mutations in the DMD gene are predicted to affect all dystrophin products except Dp71 (Table 1) .
Molecular and neuropsychological data in BMD and DMD patients with mutations predicted to affect all dystrophin products (BMD and BMD patients of group I)
The first group corresponds to a cohort of 54 patients, 42 DMD and 12 BMD, with molecular abnormalities in the DMD gene extending to, or located in the genomic region corresponding to Dp71 isoform (Table 1 ). For some of these patients (indicated in Table 1 by asterisks), we have previously reported clinical phenotypes and molecular data (19, 24, 26) . In this study we expanded the cohort of patients and discussed potential correlations between DMD mutations and cognitive deficit.
For BMD patients described in this study, and in accordance with the clinical phenotype, analysis of available muscle biopsies (deltoid or quadriceps) of the 12 Becker-type patients showed the presence of significant residual amount of dystrophin with either an apparently normal or reduced molecular weight (Table 1) . Besides the patient with a missense mutation (patient 4620, p.Asp3368His), mutations in BMD patients correspond to nonsense (patients 4295, R1181 and 6651, Table 1 ). Molecular mechanisms underlying dystrophin products expressions were uncovered through RT-PCR analyses using muscle total RNA. With the exception of three patients described below, these analyses showed the presence of at least two mRNA species: one non functional mRNA species resulting from aberrant splicing events, or bearing nonsense (or frameshift) mutations, and one functional in-frame mRNA species, resulting from normal (for splice mutations) or alternative splicing and/or mutation-associated skipping of the mutated exon (Table 1 ). In the remaining three BMD patients with either nonsense (patient 6651, c.10910C>A), splice mutation (patient 7434, c.10554-18C>G), or deletion of exons 75 and 76 (patient 2205, c.10554-10921del), no dystrophin labelling was seen with Dys-2 antibody directed against the most C-terminal amino-acids of the protein, while labelling with the antibody specific to the N-terminal domain revealed the presence of a significant amount of dystrophin with a slightly reduced molecular weight (Data not shown). Also, for these three patients Dystrophin mRNA analysis by RT-PCR, using total RNA extracted from muscle biopsy, did not reveal any alternative splicing events in the region of the mutated exons (data not shown). Thus the detected dystrophin protein is likely to correspond to "functional" dystrophin lacking amino acids downstream to the nonsense, frameshift, or deleted exons.
As shown in table 1, cognitive development and adaptive skills evaluated either through clinical follow-up and school performances, or intelligence testing revealed that 7 out of the 12 BMD patients performed in the normal range whereas 5 BMD patients have a significantly reduced IQ ranging from 45 to 70 and are therefore classified as mildly (4 patients) to severely (1 patient) mentally retarded.
Interestingly mutations detected in these patients correspond to the two cryptic splice mutations in intron 62 (patients 5539 and 5945, Table 1 ) and to the mutations described above and that led to an undetectable dystrophin with Dys-2 antibody (patients 2205, 7534, 6551, Table 1 ).
In order to further assess the consequences of mutations detected in BMD patients on Dp71 expression and provide insights into the understanding of the pathogeny of cognitive impairment, we investigated the consequences of some mutations on Dp71 transcripts and protein expression. As Dp71 is known to be expressed in lymphoblasts and fibroblasts, and not in muscle, we used available patients' lymphoblasts and fibroblasts to assess Dp71 expression. Needless to say that these cells are far from being optimal to address the relation between Dp71 expression and cognitive function. However, in the absence of appropriate biological resources, we thought it is reasonable to use these cells to assess Figure 1A, B) . In the BMD patient with the c.9225-647A>G splice mutation (patient 5539), RT-PCR using a forward primer in Dp71 specific first exon and reverse primer in exon 63 amplified only the fragment corresponding to the abnormal out of frame transcript with an insertion of the 67 nt cryptic exon ( Figure 1A ). In accordance with this result, no Dp71 protein was detected by Western blot analysis using the patient's lymphoblasts protein extract ( Figure 1C ). This result contrasts with the detection in the patient's muscle biopsy of residual amount of normal dystrophin transcript, and protein (data not shown).
In the second BMD patients with mild mental retardation (Patient 7434, Table 1 ) and splice mutation:
c.10554 -18C>G, RT-PCR experiments using RNA extracted from lymphoblasts detected only an outof-frame mRNA with an insertion of an intronic sequence corresponding to the 17 nucleotides upstream to the acceptor splice site of exon 75 ( Figure 1B) . At the protein level ( Figure 1C ), as expected no protein was detected with Dys2 antibody. However, because of the lack of sensitive antibodies directed against the N-terminal part, and that detect Dp71 in lymphoblast, it was not possible to assess whether the mutation results in a truncated Dp71 or an absence of Dp71. Table 1 ).
In addition to BMD patients, group I includes also 42 DMD patients with mutations predicted to affect all dystrophin products. Mutations detected in these patients include 13 splice mutations, 19 nonsense mutations, 4 frameshift mutations, 3 out of frame, and one distal deletion (exons 45-79), one in frame deletion encompassing exon 64, and one missense mutation, Table 1 ). Though at first sight mutations appear to be distributed throughout the distal part of the DMD gene, it is worth mentioning the relative high frequency of mutations (17/42) in exon 70 and their flanking splice sites.
Among these 42 DMD patients, cognitive tests were carried out and mean IQ values were available for 25 patients (Tables 1 and 2 ), while, for the remaining 17 DMD patients, the level of cognitive development and intellectual performance was estimated through clinical follow-up and school performances. As far as cognitive and intellectual function are concerned, all the 25 tested patients, have a IQ in the range of 35 to 55, except the patient 4062 bearing the c.10223+1G>A mutation (Table 1 ). For this patient the IQ was significantly reduced, but not in the range of those with severe MR and WISC-III tests at the age of 10 years revealed an IQ of 70. Interestingly, this latter patient has 7 years old affected nephew bearing the same mutation associated with severe language impairment, learning delay and an IQ below 50. For the remaining 17 DMD patients, clinical evaluation of cognitive performance, adaptive skills and school performances revealed severe neurodevelopmental and learning delay compatible with severe MR (Table 1) .
Analysis of mutations consequences on Dp71 transcripts and protein expression in lymphoblasts or fibroblasts was performed in 9 DMD patients of this group (patients 2297, 2893, 4062, 2895, 4248, 5740, 1585, 0994, 1585; Table 1 For the 24 DMD patients of this group, identified mutations include 14 out of frame deletions that encompass exons corresponding to Dp116 isoform, 3 out of frame duplications with a 5' end located downstream to exon 55, 4 nonsense mutations, two splice mutations and one frameshift mutation predicted to affect all dystrophin products, except Dp71 expression (Table 1) . Among these 24 DMD patients, cognitive evaluations were carried out and IQ values were available for 16 patients (Tables 1   and 2 ). For the remaining 8 DMD patients, the cognitive impairment was estimated through clinical follow-up and school performances ( Table 1) Table 1 ), and as illustrated in figure 2 (patient 7958), a significant amount of Dp71 protein was detected.
Discussion
In order to assess Dp71 contribution in cognitive deficit, we combined in this large study clinical, cognitive, molecular and protein data from two groups of patients with mutations predicted to have different consequences on Dp71 expression. We found that all 42 DMD patients with mutations extending to -or located in the region of Dp71 and which are predicted to affect Dp71 expression are mentally retarded, while the majority of patients with mutations disrupting all dystrophin products, except Dp71, has either normal or borderline cognitive performances. If we take into account patients for whom IQ was scored by neuro-psychometric tests, comparison of IQ distribution between DMD patients of group I and II indicates clearly that MR (IQ < 70) is significantly more frequent in group I than in group II: Fischer's Test, p<0.002; 24/25 and 5/16 patients for group I and group II respectively, and severe MR (IQ < 50) appears to be present only in DMD patients of group I (Tables 1 and 2 ).
This finding led us to question if Dp71 deficit is sufficient to affect cognitive development and induce MR, or if cognitive dysfunction is linked to the cumulative deficit of all dystrophin products, especially Dp427, Dp140 and Dp71, known to be expressed in brain. To address this question we screened the specific first exon of Dp71 in 320 mentally retarded probands (with no muscular deficit) of the European Consortium's cohort of X-linked mental retardation families, and only nonpathogenic changes were detected in this cohort of patients. Though very rare mutations in the first exon and promoter region of Dp71 can not be excluded, this result strongly suggest that severe mental retardation in DMD patients with mutations located in Dp71 region is likely to result from the cumulative effects of inactivation of Dp71 and other DMD-gene products expressed in brain structures during ontogenesis and adult stages. Among these products, Dp140 had previously been suggested to contribute to mental retardation Bardoni et al., 2000) . However, as the study described here is focused on Dp71 and all patients included in this study bear mutations predicted to alter Dp140 expression, the contribution Dp140 in cognitive impairment cannot be evaluated. To overcome this limitation, we reviewed clinical and molecular data concerning patients referred to our diagnostic laboratory, and undertook a comparative study in two additional large groups of patients differing by mutations consequences on Dp140 expression (details concerning these patients are (DMD patients of group II,   table 2 ). Though mutations leading to loss of function of Dp427 and Dp140 do not systematically result in cognitive deficit, these data as well as those reported in the literature (21, 22) are consistent with a contribution of Dp140 deficit in the pathogeny of mild cognitive impairment.
The systematic occurrence of mild to severe mental retardation in DMD patients of group I contrasts with the heterogeneous cognitive profiles observed in the 24 DMD patients with mutations extending to -or located in exons 56 to 62 (or 45 -55) which are predicted to affect all dystrophin products except Dp71 (or except Dp71 and Dp116). In order to further assess the contribution of Dp71 in the pathogeny of cognitive impairment, we focused on patients for whom IQ value was available and compared distributions of IQs in DMD patients of group I and II. (36) . However, Dp71 function in neuronal cells and synapses, and its accurate role in the development of cognition remains still largely unknown. To address this issue, we have recently carried out complementary approaches, using wild type and Dp71-null mice, and we found expression of Dp71 at both pre-and postsynaptic compartments of excitatory synapses. We found that Dp71-associated protein complexes interact with specialized modular scaffolds that cluster glutamate receptors and organize signalling in postsynaptic densities. We further showed that Dp71-null mice display abnormal synaptic organization and maturation in vivo, abnormally enhanced glutamate transmission and altered synaptic plasticity in CA1 hippocampal area (F.Daoud and J.Chelly, manuscript in preparation). In conclusion, in addition to the diagnostic consequences, i.e., DMD and BMD patients with severe mental retardation should be first tested for mutations in Dp71 region, these findings suggest that Dp71 is required for development of cognitive functions and provide insights into the understanding of molecular mechanisms underlying cognitive impairment associated with DMD and BMD phenotype. were available, dystrophin analysis was performed by immunofluorescence analysis of cryo-sections as described by Bornemann et al. (37) , and/or multiplex Western blot analysis using previously reported procedure. In both procedures monoclonal anti-dystrophin antibodies from Novocastra (Newcastle, UK) were used. For some patients, the diagnostic strategy included dystrophin cDNA analysis and sequencing. Briefly, total muscle RNA extraction using the RNA Plus kit (Q-BiOgene, Carlsbad, CA) was performed according to the manufacturer's protocol. Dystrophin mRNA was amplified by RT-PCR as 14 overlapping fragments, which were subsequently analysed by electrophoresis on a 2% agarose gel, then either scanned by protein truncation test (PTT) (38), or directly sequenced using a Big Dye Terminator I kit and ABI 377 equipment (Applied Biosystem, Courtaboeuf, France) (26) . All mutations detected, or suspected through mRNA analyses were confirmed by sequence analysis of targeted genomic regions of the DMD gene using patient's genomic DNA. For some patients included in this report (Table 1: Patients indicated by asterisks) mutations and clinical data have been described in previous study (19, 24, 26) .
Dp71 mRNA and protein analysis, and screening of Dp71 first specific exon in MR
Consequences of DMD mutations on Dp71 mRNA and protein expression were assessed by RT-PCR and Western blot in patients for whom lymphoblastoid cell lines and primary cultures of fibroblasts were available. Briefly, total lymphoblasts (or fibroblasts) RNA was obtained by acid guanidium thiocyanate-phenol-chloroform extraction using RNA Plus (Q-BiOgene, Carlsbad, CA) in accordance with the manufacturer's protocol. Dp71 mRNA was analysed by RT-PCR using primers located in Dp71 exons, including the specific first exon. The design of these primers was driven by the position of mutations and predicted consequences on transcripts maturation. Amplified RT-PCR fragments were analysed by electrophoresis on 2% agarose gel, and direct sequencing. Protein analysis was performed on lymphoblasts (or fibroblasts) protein extracts by Western blot method using standard protocols and Dys8/6C5 antibody (NCL-DYS2/dystrophin C-ter from Novocastra, Newcastle, UK) directed against the C-terminal part of dystrophin and recognizing Dp71. In this study we also included 7 patients exhibiting MR and severe behavioural problems and psychiatric clinical features for whom it was not possible to score cognitive performances and provide IQ levels. We excluded 4 mentally retarded DMD and BMD patients with mutations criteria that meet those of group I or II patients. However, in two cases, clinical history of the family indicated the presence of a potential X-linked mental retardation condition that independently segregates from the muscular phenotype. For the two other patients, brain imaging investigations revealed the presence of basal ganglia calcifications in one patient, and cerebellar hypoplasia and cortical atrophy in the second one.
Additional information
Molecular and clinical data reported in this paper will also be available in the public LSDB 
